CLDF Title
Home | Contact Us | Bookmark
NASH HCC LiverQ Academy
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: AbbVie's drug for all types of hepatitis C wins EU approval

AbbVie's drug for all types of hepatitis C wins EU approval

Last Updated: 2017-07-28

By Reuters Staff

(Reuters) - AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.

The company said the approval of Maviret was supported by eight studies evaluating more than 2,300 patients in 27 countries.

The drug, a combination of glecaprevir and pibrentasvir, showed 97.5 percent cure rate in the eight weeks of treatment of patients, who have never undergone treatment.

The drug is also under priority review by the U.S. Food and Drug Administration and the company expects regulatory decisions in the coming weeks.

The FDA last year approved a combination drug, a 12-week regimen by Gilead Sciences Inc for the treatment for all six major forms of hepatitis C for patients who've already tried one drug.

AbbVie also competes with companies such as Merck and Co in the hepatitis C market.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.